Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Hematologic Oncology

Breast Cancer

Gastrointestinal Cancer

Hematologic Oncology

SL-401 Emerging as First Targeted Therapy for Rare Blood Cancer

Naveen Pemmaraju, MD, discusses SL-401 and the future of treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Read More >>

Importance of NGS and Targetable Mutations Stressed in AML

FDA Grants SL-401 Priority Review for Rare Hematologic Cancer

Patient-Reported Outcomes With Stem Cell Transplant Signal Progress in Myeloma

FDA Approves Mogamulizumab for CTCL

Selinexor FDA Submission Completed for Multiple Myeloma

View More Stories >>

View Conference Coverage

2018 International Lung Cancer Congress

2018 Pan Pacific Lymphoma Conference

2nd Annual Live Medical Crossfire® : Hematologic Malignancies

State of the Science Summit on A Summer of Progress: Updates from ASCO 2018

2018 State of the Science Summit on Breast Cancer

Challenges in the Treatment of Patients With MCL

Dr. Smith Discusses the Diagnosis of Double-Hit Lymphoma

Dr. Holstein Discusses Triplets and Quadruplets in Myeloma

$Dr. Garcia-Sanz on Combination Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma$

Dr. Pemmaraju on the Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

$Dr. Eyre on Results of Venetoclax in Relapsed/Refractory MCL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Optimizing the Use of BCR-ABL TKIs in CML

CML: Considering Second-Generation TKIs

TIDEL-II: Switching From Imatinib to Nilotinib in CML

When to Switch Therapy in Chronic Myeloid Leukemia

RT PCR Testing in CML: Finding BCR-ABL TKI Candidates

OncLive houses thousands of videos that provide updates and information.
See more Videos

The Evolving Treatment Landscape of CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

Relapsed/Refractory CLL: Evaluating Other Novel Agents

$Novel Approaches to Treating Relapsed/Refractory CLL$

Novel Approaches to Treating Relapsed/Refractory CLL

$Continuing Therapy in Relapsed/Refractory CLL$

$Evaluating Pharmacologic Agents in Relapsed/Refractory CLL$

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

$Approaching Therapy for Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

2015 ASH Annual Meeting Highlights

Gina Columbus highlights findings from the 2015 American Society of Hematology Annual Meeting and Exposition, including advances in multiple myeloma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.View Now

Multiple Myeloma: Emerging Concepts in Management

This Peer Exchange discussion, moderated by A. Keith Stuart, MB, ChB, highlights the most up-to-date information available on the emerging concepts in the management of multiple myeloma. View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approval in CTCL, Breakthrough Therapy Designation in CRC, and More